Prophylaxis of complications after pancreatic surgery: Results of a multicenter trial in Italy

C. Bassi, M. Falconi, D. Lombardi, G. Briani, S. Vesentini, M. G. Camboni, P. Pederzoli, M. Battistoni, S. Pedrazzoli, C. Pasquali, R. Dionigi, G. Carcano, V. Di Carlo, A. Zerbi, G. P. Marzoli, F. Martin, U. Valente, V. Casolino, G. Uomo

Research output: Contribution to journalArticlepeer-review


An Italian prospective multicentre study evaluated the efficacy of octreotide, a synthetic somatostatin analogue, in preventing the complications of elective pancreatic surgery. 303 patients with tumours of the pancreas or the ampullary region, in whom ultrasonography and computed tomography scan had shown a resectable lesion, or with chronic pancreatitis, were randomized in a double-blind fashion to treatment with octreotide 100 μg t.i.d. s.c. starting at least 1 h before surgery and continued till the 7th postsurgical day, or with matching placebo. Unresectable lesions were found at laparatomy in 31 patients (15% of those with tumours). In 14 others, procedures not anticipated in the study protocol had to be performed, and in 6 additional cases there were other protocol violations so that these 20 patients were excluded from the study analysis. Considering the 252 evaluable patients, the complication rate was significantly higher in the 130 placebo-treated patients than in the 122 who received octreotide (29.2 vs. 15.6%; p = 0.01). We therefore suggest that octreotide may substantially reduce the risk of complications after elective pancreatic surgery.

Original languageEnglish
Pages (from-to)41-47
Number of pages7
Issue numberSUPPL. 1
Publication statusPublished - 1994


  • Chronic pancreatitis
  • Octreotide
  • Pancreas neoplasms
  • Pancreatic surgery
  • Resectability

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Prophylaxis of complications after pancreatic surgery: Results of a multicenter trial in Italy'. Together they form a unique fingerprint.

Cite this